# 1 Phenome-wide HLA association landscape of 235,000

# 2 Finnish biobank participants

- 3 Jarmo Ritari<sup>1\*</sup>, Satu Koskela<sup>1</sup>, Kati Hyvärinen<sup>1</sup>, FinnGen<sup>2</sup>, Jukka Partanen<sup>1\*</sup>
- 4 <sup>1</sup>Finnish Red Cross Blood Service, Helsinki, Finland
- 5 <sup>2</sup>Full list of participants and affiliations available as a supplementary file
- 6 \*Correspondence: jarmo.ritari@bloodservice.fi; jukka.partanen@bloodservice.fi

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 7 Abstract

- 8 The human leukocyte antigen (HLA) system is the single most important genetic
- 9 susceptibility factor for many autoimmune diseases and immunological traits.
- 10 However, in a range of clinical phenotypes the impact of HLA alleles or their
- 11 combinations on the disease risk are not comprehensively understood.
- 12 For systematic population-level analysis of HLA-phenotype associations we
- 13 imputed the alleles of classical HLA genes in a discovery cohort of 146,630 and
- 14 replication cohort of 89,340 Finns of whom SNP genotype data and 3,355 disease
- 15 phenotypes were available as part of the FinnGen project.
- 16 The results suggest HLA associations in phenotypes not reported previously and
- 17 highlight interactions between HLA genes and alleles in autoimmune diseases.
- 18 Furthermore, shared HLA alleles in autoimmune and infectious diseases support
- 19 a genetic link between these diseases.

# 20 Introduction

21 Regulation of adaptive immune system function is based on recognition of

- 22 foreign antigens and infectious agents by human leukocyte antigen (HLA)
- 23 receptors encoded by highly polymorphic loci within the major histocompatibility
- 24 complex (MHC) on chromosome 6. Out of more than 200 genes harbored by the
- 25 MHC region approximately half have known immune-related functions (The MHC
- 26 sequencing consortium, 1999). The HLA molecules play a key role in the
- 27 initiation of immune response by binding internal (HLA class I molecules A, B, C)
- and external (HLA class II molecules *DR*, *DQ*, *DP*) peptides and presenting them
- 29 to T lymphocytes. While class I receptors present antigens directly to cytotoxic
- 30 CD8+ T cells, the class II molecules are recognized by CD4+ T cells that polarize
- 31 into different regulatory subtypes (A. Barr et al., 2012). The extremely high
- 32 genetic polymorphism of HLA genes results in structural variation in the peptide
- 33 binding pockets between HLA alleles, consequently leading to different peptide-
- 34 binding preferences and varying antigen repertoires presented to T cells.
- 35 Originally discovered over 50 years ago as the major determinant of organ and
- 36 hematopoietic graft rejection (Thorsby, 2009), genetic variation in HLA has since
- 37 been linked to a wide spectrum of immunological diseases (Trowsdale and
- 38 Knight, 2013). In major multifactorial autoimmune diseases, HLA alleles and their

39 protein-level motifs present the most important single genetic component in 40 disease susceptibility (Matzaraki et al., 2017), even though in most diseases the triggering peptide complexing with the implicated HLA protein polymorphism 41 42 remains unknown (Dendrou et al., 2018). On the other hand, varving degrees of 43 protective allelic effects as distinguished from the absence of strong 44 susceptibility alleles have been reported for major autoimmune disorders 45 (Bettencourt et al., 2015; van der Helm-van Mil et al., 2005; van Lummel et al., 46 2019). The effect towards the reduction of disease risk is presumably mediated 47 through presentation a favourable selection of antigens in terms of specificity 48 and self-regulation (Tsai and Santamaria, 2013). Accordingly, both susceptibility 49 and resistance effects have been attributed to amino acid residues and their 50 positions in the HLA protein sequence (Furukawa et al., 2017: Gregersen et al., 51 1987; Raychaudhuri et al., 2012). Different alleles sharing a similar structural 52 motif also manifests in local epistasis. Detailed analyses of large cohorts of 53 patients with rheumatoid arthritis or type 1 diabetes have demonstrated that the 54 MHC-mediated risk can be pinpointed to specific amino acid positions, and the 55 effect is being modified non-additively by amino acid polymorphisms in a few other positions in the same or different class II gene (Hu et al., 2015; Lenz et al., 56 57 2015: Okada et al., 2016).

58 HLA allelic variance can cause differences in the strength of immune response 59 against infectious agents such as HIV by differential preference of viral peptides 60 (The International HIV Controllers Study, 2010). However, in case of structural 61 similarity between pathogen T cell epitope and a host peptide, immune reaction against the antigen may also increase the likelihood of developing autoimmunity 62 63 (Oldstone, 1998). Predisposition to infections before the onset of an autoimmune 64 condition has been reported in several cases (Sfriso et al., 2010), and reaction of 65 host T cell clones against the pathogen epitope mimicking host structures has 66 been demonstrated experimentally (Wucherpfennig and Strominger, 1995). Nevertheless, exposure to a rich microbial environment also contributes to 67 68 achieving protective, tolerogenic setting through toll-like receptor, regulatory T 69 cell and interleukin signaling (Bach, 2018). Immunological regulation and its 70 perturbation are therefore dependent on both environmental and host genetic 71 factors that are mediated by individually varying HLA presentation.

72 Large biobank genome data collections combined with electronic health records

73 have made phenome-wide association studies (PheWAS) feasible (Denny et al.,

74 2013), leading to increased power and novel discoveries in disease genetics

75 (Diogo et al., 2018; Liu et al., 2016; Verma et al., 2018). Population-based 76 approach for the analysis of phenotypic spectrum of HLA associations can give 77 novel insights into the architecture of well-established autoimmune and immune 78 disease associations and broaden the view toward other traits as well (Hirata et 79 al., 2019; Karnes et al., 2017; Liu et al., 2016). The first reported HLA PheWAS 80 analysis with over 11,000 individuals found eight novel phenotypes linked with MHC SNPs as well as five previously unknown associations across multiple 81 82 phenotypes (Liu et al., 2016). Karnes and coworkers (2017) imputed HLA alleles 83 from cohorts of 28,839 and 8,431 individuals of European origin and tested HLA 84 associations with 1,368 phenotypes. 104 significant associations were observed 85 with 29 phenotypes and 29 HLA alleles. In addition to well-established HLA associations, four novel phenotypes were reported. Hirata and coworkers (2019) 86 87 analyzed 106 clinical phenotypes for association with MHC variation in a cohort 88 of 166,190 individuals from Japan. They reported significant genotype-phenotype 89 associations in 52 phenotypes, and their fine-mapping showed multiple different 90 patterns of HLA associations, some of which were independent from classical 91 HLA genes.

92 Here we report a systematic, population-based association study of imputed HLA 93 alleles in 3,355 phenotypes in discovery and replication cohorts of 146,630 and 94 89,340 individuals, respectively. These large single-population cohorts enabled 95 us to perform HLA analysis in diseases not studied in detail before and to reveal 96 cross-phenotype dependencies of allelic associations particularly between 97 autoimmune and infectious diseases. Furthermore, as a systematic examination of risk-modifying effects have not, to our knowledge, been implemented at 98 99 biobank-scale to date, we sought to define protective allelic effects as opposed 100 to nonpredisposition to the top risk alleles. To this end, we studied heterozygous 101 risk allele genotypes, and hypothesized that a risk allele effect could also be 102 modified by a HLA locus of a different class.

#### 103 Results

#### 104 Associations of imputed HLA alleles


Altogether 155 four-digit HLA alleles were imputed with posterior probability >
0.5, and of these, 84 alleles had at least one confirmed association in both
cohorts. In total, we found 3,649 statistically significant HLA-allele-phenotype

4

108 associations in 368 phenotypes (Supplementary Table 1). Supplementary Figure

- 109 1 summarises the distribution of allele associations across the main phenotype
- 110 categories for each HLA gene. HLA class II genes harboured both the largest
- 111 number of associations and the strongest associations as indicated by their
- 112 effect sizes. The top disease categories in terms of number of associations were
- 113 type 1 diabetes and rheumatic diseases. We did not find a relationship between
- 114 the number of significant associations and the number of available cases in a
- 115 phenotype (Supplementary Figure 2).
- 116 1,620 of the 3,649 replicated HLA associations were in diabetes-related traits
- 117 (Supplementary Table 1) with *DQB1\*03:02* as the top risk allele. Celiac disease
- 118 (CD) had the second highest number of HLA associations. The lowest p-values
- were for *DRB1\*03:01*, *DQA1\*05:01* and *DQB1\*02:01* followed by other alleles
- 120 known to be in a strong linkage disequilibrium with this HLA class II haplotype.
- 121 To validate our analysis we compared our results with previously published HLA
- 122 PheWAS studies (Hirata et al., 2019; Karnes et al., 2017; Liu et al., 2016). We
- 123 observed a consistent relationship between the obtained odds ratios of
- 124 associated HLA alleles or genes and those of the three other previously published
- 125 HLA PheWAS studies (Figure 1a). Further, to evaluate the consistency of
- 126 associations between the discovery and replication cohorts, we correlated the
- 127 logistic regression log-odds ratios (betas) for the three types of analysis
- 128 implemented here: HLA allele, diplotype and haplotype. Expectedly, we observed
- 129 a strong correlation between the two independent cohorts (Pearson's correlation
- 130 coefficient about 0.9; Figure 1b).
- 131 We discovered statistically significant (discovery FDR < 0.01, replication p <
- 132 0.01) HLA allele associations in seven phenotypes for which we found scarce
- 133 prior evidence of HLA association in the literature (Table 1). For example, we
- 134 observed an association for *DQA1\*01:03* and *DQB1\*06:03* in mental and
- 135 behavioural disorders due to cannabinoids (p-value =  $10^{-5}$ ; beta = 0.6).
- 136 Moreover, drug-induced hypoglycaemia without coma, vitreous haemorrhage,
- 137 otitis externa, acute sinusitis, and trigger finger were all associated with
- 138 DQB1\*03:02 and scleritis and episcleritis was associated with B\*27:05.

It is made available under a



- 139 Figure 1. Comparison of HLA association effects. a) Odds ratios of previously
- 140 reported HLA PheWAS associations (x-axis) vs. the discovery cohort of the
- 141 present study (y-axis). Depending on the study, associations are shown either at
- 142 the level of four-digit alleles (Karnes et al.) or at gene-level tagged by the
- 143 highest ranking variant (Liu et al. & Hirata et al.). b) Correlation of HLA
- 144 association FDR < 0.01 log-odds ratios (betas) between the discovery cohort (x-
- 145 axis) and the replication cohort (y-axis) of the present study. Panels from left to
- 146 right show the data for HLA allele, genotype, and two-locus haplotype association
- 147 analyses.

- Table 1. HLA allele associations and modifying effects in previously poorly 148
- 149 studied phenotypes. Diplotype and haplotype analyses show effects of
- 150 combinations of two alleles. Here, a strong protective effect on the risk allele can
- 151 result in non-significant association.

Type of analysis	Phenotype	Primary HLA	Modifying HLA	Discovery			Replication	
				<i>p</i> -value	Beta	SE	Beta	SE
allele	Drug-induced hypoglycaemia without coma	DQB1*03:02		4.14E-05	0.667	0.155	0.917	0.173
		DQA1*03:01		4.83E-05	0.663	0.155	0.926	0.173
	Mental and behavioural disorders due to cannabinoids	DQA1*01:03		7.26E-06	0.603	0.128	0.439	0.127
		DQB1*06:03		1.22E-05	0.59	0.128	0.413	0.129
		DRB1*13:01		3.23E-05	0.54	0.125	0.378	0.125
	Vitreous haemorrhage	DQB1*03:02		1.36E-24	0.701	0.064	0.726	0.079
		DQA1*03:01		1.33E-23	0.688	0.065	0.707	0.079
		DRB1*04:01		4.61E-13	0.552	0.073	0.765	0.085
	Otitis externa	DQB1*03:02		1.39E-05	0.221	0.051	0.212	0.058
		B*18:01		2.46E-05	0.291	0.068	0.341	0.08
		DQA1*03:01		4.32E-05	0.209	0.051	0.208	0.059
	Acute sinusitis	DQA1*03:01		1.97E-07	0.147	0.028	0.145	0.033
		DQB1*03:02		2.66E-07	0.145	0.028	0.142	0.032
		DRB1*04:01		7.41E-06	0.142	0.032	0.134	0.036
	Trigger finger	DQB1*03:02		7.39E-08	0.333	0.061	0.261	0.074
		DQA1*03:01		7.67E-08	0.333	0.061	0.257	0.074
		DRB1*04:01		1.88E-06	0.328	0.068	0.357	0.079
	Scleritis and episcleritis	B*27:05		8.48E-08	0.579	0.102	0.574	0.122
diplotype	Lichen planus	DQB1*05:01	DQB1*05:01 a	2.46E-14	1.323	0.166	1.400	0.216
			DQB1*03:01	2.26E-02	0.385	0.165	0.621	0.201
	Seropositive rheumatoid arthritis	DRB1*04:08	DRB1*04:01 a	5.84E-35	1.739	0.146	2.490	0.204
			DRB1*08:01	2.50E-01	0.205	0.223	0.226	0.384
	Co-morbidites, CVD and metabolic diseases	DRB1*04:01	DRB1*03:01 a	1.27E-76	0.953	0.052	0.877	0.068
			DRB1*15:01	6.61E-01	0.020	0.045	-0.067	0.061
			DRB1*11:01	9.20E-01	0.009	0.089	0.204	0.124
			DRB1*14:54	3.38E-01	-0.167	0.177	-0.026	0.24
	Thyroiditis, ILD-related definition	DQB1*02:01	DQB1*03:02 a	4.71E-15	1.203	0.134	0.989	0.172
			DQB1*05:01	8.74E-03	0.387	0.144	-0.112	0.207
haplotype	Type1 diabetes, definitions combined	DQB1*03:02	B*44:27 <sup>a</sup>	7.24E-14	2.223	0.255	2.190	0.309
			B*40:01	6.04E-08	0.885	0.15	1.129	0.165
			B*27:05	3.50E-06	0.823	0.164	0.713	0.214
	Diabetes, kidney failure	DQB1*03:02	B*56:01 <sup>a</sup>	8.34E-19	1.333	0.129	1.240	0.177
			B*27:05	3.86E-03	0.518	0.173	-0.355	0.366
			B*18:01	1.58E-02	0.371	0.149	0.486	0.19
	Diabetic maculopathy	DQB1*03:02	B*56:01 <sup>a</sup>	1.34E-17	1.353	0.136	1.502	0.176
			B*18:01	4.83E-04	0.548	0.15	0.656	0.191
			B*27:05	3.70E-01	0.217	0.215	-0.171	0.366
	ILD Co-morbidites, CVD and metabolic diseases	DRB1*04:01	B*44:27 <sup>a</sup>	1.51E-06	0.695	0.147	0.586	0.18
			B*44:02	8.63E-03	0.100	0.038	0.042	0.052
	Other (seronegative) rheumatoid arthritis, wide	B*27:05	DRB1*04:08 a	2.04E-19	1.046	0.102	0.978	0.132
			DRB1*04:04	8.75E-01	0.047	0.191	0.090	0.249

<sup>a</sup> Protective effect was determined relative to this allele combination in diplotype and haplotype analyses.

#### 152 Cross-phenotype HLA allele associations


153 To evaluate possible independence of an HLA association between two 154 phenotypes, we conducted analyses by including a phenotype as an additional 155 covariate in the regression models. We observed that altogether 68 HLA alleles 156 showed evidence of independent association with two or more phenotype 157 categories (Supplementary Table 2). To study shared HLA associations in 158 autoimmune and infectious diseases, we narrowed down the results for these 159 phenotypes to include only alleles that in conditional analyses showed evidence 160 of associating with infectious diseases independently of at least one autoimmune 161 disease. The results are summarized by Figure 2, showing the alleles, p-values, 162 phenotypes and effect sizes of the associations. We found 12 alleles in five 163 infectious and five autoimmune diseases that fulfilled the above criteria of association. Nine HLA alleles, eight of which appeared to be parts of C\*07:01 -164 165 B\*08:01 - DRB1\*03:01 - DQA1\*05:01 - DQB1\*02:01 and DRB1\*04:01 -166 DQA1\*03:01 - DQB1\*03:02 haplotypes, as well as B\*13:02, predisposed to both 167 autoimmune diseases and infections. Three alleles, all part of the DRB1\*13:01 -168 DQA1\*01:03 - DQB1\*06:03 haplotype, showed a lower frequency in cases. 169 Altogether ten alleles associated with two or more infectious-autoimmune

170 disease pairs.

#### 171 HLA diplotype associations


- 172 To analyze the effect of HLA risk allele diplotypes on the level of disease
- 173 susceptibility, we conducted conditional regression analyses with diploid allele
- 174 combinations. We found 225 statistically significant (discovery FDR < 0.01,
- 175 replication p < 0.01) phenotypes representing 21 different phenotype categories
- associated with at least one risk allele diplotype (Supplementary Table 3). In 91
- 177 phenotypes representing 13 different phenotype categories the other HLA allele
- in the same locus exerted a statistically significant (discovery FDR < 0.01,
- replication p < 0.01) modifying effect on the risk allele (Supplementary Table 4).
- 180 Figure 3 shows significant modifying allelic effects in phenotypes that deviated
- 181 the most from expectation (i.e. the sum of individual allele effects, Figure 3a).
- 182 For example, in type 1 diabetes, the results replicated the well-estalished
- 183 protective allele *DQB1\*06:02* and showed that *DQB1\*04:02* increased the
- 184 DQB1\*03:02 mediated risk for insulin medication despite having negative effect

- It is made available under a
- 185 direction (-0.16) in the allele-level association analysis (Figure 3b). In coeliac
- disease, alleles such as DQB1\*06:03 or DQB1\*04:02, that showed negative beta 186
- 187 values in the single allele association test, contributed towards increasing the
- 188 DQB1\*02:01 mediated risk (Figure 3b). Potentially novel heterozygotic effects on
- 189 the risk allele are listed by Table 1.



190 Figure 2. HLA alleles associated with an infectious disease independently of 191 autoimmune disease. **a)** P-values of significant ( $< 5 \times 10^{-8}$ ) alleles. Each panel 192 show an infectious disease phenotype. Within panels, one allele can associate 193 with more than one autoimmune disease. b) HLA alleles associated with 194 infectious diseases (y-axis) independently from autoimmune diseases (x-axis). 195 The color-filled squares indicate the effect size and direction. The results are 196 grouped by known haplotypes in each row. DQA1\*05:01 is omitted from the first 197 row as its profile is indentical to the other two shown class II alleles. The data are based on conditional regression analyses with  $p < 5 \times 10^{-8}$  threshold in the full 198 199 dataset (discovery+replication), where selected phenotypes were analysed by 200 adding a different phenotype as an additional covariate in the model one at a 201 time.





202 Figure 3. HLA diplotype effects. Risk allele in combination with the second allele 203 of the same HLA gene. a) Phenotypes in which the risk allele diplotype 204 association effects deviate from expected (i.e. sum of individual allelic effects).

- 205 b) The x-axis shows log-odds ratios (betas) for different diplotypes depicted on
- 206 the y-axis. The y-axis label indicates the primary risk allele, and the tick mark
- 207 labels indicate the other alleles in the same locus. The vertical dashed lines
- 208 indicate the risk allele's effect estimates based on allele-level analysis. Only
- 209 significant (discovery FDR < 0.01, replication p < 0.01) effects on the risk allele
- 210 are shown. The error bars indicate standard errors for the beta values.


#### 211 HLA haplotype associations

212 To test whether the effect of a primary risk allele was affected by alleles of a HLA 213 gene of a different class, we conducted conditional regression analyses with 214 allele combinations from two HLA genes (termed here as haplotype 215 associations). The analysis was performed using phased data but we cannot 216 prove that they genuinely formed haplotypes. We found a total of 16 statistically 217 significant haplotype associations with 224 phenotypes representing 23 different 218 phenotype categories (Supplementary Table 5). There was a statistically significant (discovery FDR < 0.01, replication p < 0.01) modifying effect on the 219 220 risk allele in 56 phenotypes representing 10 phenotype categories 221 (Supplementary Table 6). Figure 4a shows significant modifying allelic effects in 222 phenotypes that deviated the most from expectation (i.e. the sum of individual 223 allele effects). For example, in T1D, even though B\*44:27 by itself was not 224 associated, together with DQB1\*03:02 the risk is increased (Figure 4b). 225 Potentially novel haplotype modifier effects on the risk allele are listed by Table 226 1.

#### 227 Discussion

228 The current study presents results of a systematic association analysis of 229 imputed HLA alleles with over 3,000 clinical phenotypes in more than 235,000 230 individuals. In total, we report 3,649 statistically significant and successfully 231 replicated allele-phenotype associations in 368 phenotypes distributed over 35 232 disease categories. Consistently with previous HLA PheWAS and other reports 233 (Dendrou et al., 2018), our study uncovered well-established associations with 234 major autoimmune disorders, and also found evidence of HLA pleiotropy (Karnes 235 et al., 2017; Liu et al., 2016) in particular between infectious and autoimmune 236 diseases. Expectedly, the effect size estimates between the previous studies and 237 our discovery and replication data sets showed overall high concordance, 238 validating the accuracy of HLA imputation, phenotype data and association 239 analyses based on these. The results from conditional analyses focusing on 240 selected combinations of HLA alleles and cross-phenotype associations further 241 add to the existing knowledge by including risk-modifying effects not studied 242 before in a phenome-wide context.





243 Figure 4. HLA haplotype effects. Risk allele in combination with another allele 244 of a different HLA gene. a) Phenotypes in which the risk allele haplotype 245 association effects deviate from expected (i.e. sum of individual allelic effects). 246 b) The x-axis shows log-odds ratios (betas) for different two-locus allele combinations depicted on the y-axis. The y-axis label indicates the primary risk 247 248 allele and the tick marks indicate alleles of a different HLA gene. The vertical 249 dashed lines indicate the risk allele's effect estimates based on allele-level 250 analysis. Only significant (discovery FDR < 0.01, replication p < 0.01) effects on 251 the risk allele are shown. The error bars indicate standard errors for the beta 252 values.

253 In a recent well-powered association study, MHC region was linked with multiple 254 common infectious diseases, and fine-mapping revealed several independent 255 signals among HLA-gene variants and alleles (Tian et al., 2017). Moreover, in 256 another study on MHC expression quantitative trait loci, protection from bacterial 257 infections in cystic fibrosis by the common autoimmune risk haplotype AH 8.1 258 was found to be mediated by a non-HLA gene carried in the same haplotype 259 (D'Antonio et al., 2019). Our finding that certain HLA alleles in common 260 haplotypes were shared by infectious and autoimmune diseases is intriguing in 261 regard to the proposed triggering role of infections in autoimmunity (Ercolini and 262 Miller, 2009). The result on the B\*13:02 - DOB1\*03:02 and C\*07:01 -263 DQB1\*02:01 haplotypes showed that class I and II alleles exhibited different 264 associated phenotypes, suggesting that these alleles may have effects that are 265 not explained by linkage disequilibrium alone. As evidence of HLA pleiotropy was 266 also reported by two previous MHC PheWASs (Karnes et al., 2017; Liu et al., 267 2016), it will be of great interest to try to reveal the mechanistic background for 268 these shared associations, especially between infections and autoimmunity 269 (D'Antonio et al., 2019; Matzaraki et al., 2017).

270 The strong enrichment of HLA risk alleles in autoimmune diseases, e.g. DQ8 in 271 T1D, DQ2 in coeliac disease, or B27 in arthropathies, automatically leads to 272 lower frequencies of other alleles in the risk locus and consequently to risk-273 reducing effect estimates irrespective of actual association. Conditional analyses 274 adjusted for allelic variation can reveal genuine effects of the risk-gene HLA 275 genotypes. In line with previous analyses, our HLA diplotype PheWAS replicated 276 known protective allelic effects in e.g. in demyelinating diseases (DRB1\*07:01 277 and 01:01) (Wu et al., 2010), arthropathic psoriasis (C\*07:01) (Queiro et al., 278 2006), diabetes (DQB1\*06:02) (Pugliese et al., 1995), and seropositive RA (DRB1:13:01 and 08:01) (van der Helm-van Mil et al., 2005) and provided 279 280 estimates for risk-modifying effects of a range of alleles occurring together with 281 the top risk allele in autoimmune disorders. Our results showed a risk-modifying effect of DQB1\*03:01 for DQB1\*05:01 in lichen planus (LP), helping resolve the 282 283 somewhat contradictry results obtained by previous serotyping studies on 284 frequencies of DQ1 and DQ3 in LP patients (Nasa et al., 1995; Porter et al., 285 1993).

Population founder effect can lead to reduced genetic diversity and alteredfrequencies of genetic variants (Chheda et al., 2017), including HLA alleles and

13

haplotypes (Creary et al., 2019; Hurley et al., 2020). The current study was 288 289 based on genetically defined cohort of Finns that constitute a Northern European 290 genetic isolate. A characteristic genetic architecture is visible in the repertoire of 291 HLA haplotypes where a number of Finnish enriched rare (FER) haplotypes are 292 substantially more common than elsewhere in Europe (Linjama et al., 2018). Our 293 HLA class I – class II analysis demonstrates how haplotype effects can be 294 estimated in a genetically characteristic population. We found that B\*27:05295 occurring together with DRB1\*04:08 carried the highest risk for seronegative 296 rheumatic diseases, confirming an association that has been previously 297 described in the Finnish population (Tuokko et al., 1997). This allele combination 298 occurs in C\*01:02 - HLA-B\*27:05 - DRB1\*04:08 - DOB1\*03:01 haplotype that 299 belongs to the FER group and is 3300 times more frequent in the Finnish 300 population than in other European populations. Our study further demonstrated 301 that the predisposing effect of B\*27:05 was effectively removed by DRB1\*04:04. 302 This allele pair is known to occur in the C\*01:02/02:02 - B\*27:05 - DRB1\*04:04 -

- 303 *DQB1\*03:02* FER haplotype.
- 304 While HLA class I and II have been reported to be independently associated with
- 305 T1D (Eike et al., 2009; Mikk et al., 2017), the compund effect of allelic
- 306 heterogeneity between HLA class I and II remains less comprehensively
- 307 understood. We observed protective effects for HLA class I alleles that by
- 308 themselves did not have association with T1D and its comorbidities in our
- analyses or elsewhere in the literature (Noble and Valdes, 2011). For example,
- 310 *B*\*27:05 and B\*40:01 occurring together with *DQB1*\*03:02 reduced the risk
- 311 conferred by *DQB1\*03:02* while *B\*44:27* substantially increased it. The
- 312 predisposing effect of the uncommon B\*44:27 allele in diabetes-related
- 313 conditions can go unnoticed in mixed populations due its infrequency or
- 314 appearance in different class II haplotypes. Allele *B*\*44:27 is relatively rare also
- in Finland and occurs mostly with C\*07:04 B\*44:27 DRB1\*16:01 -
- 316 DQB1\*05:02, DRB1\*08:01 DQB1\*04:02 and DRB1\*01:01 DQB1\*05:01. As
- 317 these haplotypes lack known risk alleles, the causative variant remains unknown
- 318 but suggests a potential role for *B*\*44:27. Obviously, rare alleles such as *B*\*44:27
- 319 and haplotypes carrying it are not widely studied, and also the risk factor
- 320 associated with *B*\*44:27 may not be the same as in *DQB1*\*03:02 haplotypes.
- 321 Our study is also limited in some respects. First, analysis of HLA alleles alone
- 322 cannot definitively attribute the observed associations directly to HLA owing to
- 323 strong linkage disequilibrium within the MHC (Trowsdale and Knight, 2013). For

324 example, the known associations between disorders of iron metabolism and 325 A\*03:01, and that between disorders of adrenal gland and DRB1\*04:04, at least 326 partially are a result from linkage disequilibrium with *HFE* gene and *CYP21* gene, 327 respectively. Also, most of the rare HLA alleles were not covered by the used imputation panel and consequently the analysis did not cover their possible 328 329 associations. Second, our study is restricted by statistical power particularly in 330 conditional analyses with many covariates and in endpoints having a low number 331 of cases. While the independent replication design of the study helps eliminate 332 non-systematical false positives arising from e.g. relatedness, batch and other 333 chance factors, it cannot categorically rule them out or remove sampling 334 uncertainty in low-powered endpoints. Third, the FinnGen phenotypes, albeit 335 carefully curated, were derived from health register which cannot be assumed to 336 be totally accurate. Finally, haplotype analysis cannot prove that the alleles are 337 encoded in *cis*, but the effects between two HLA genes, or chromosomal regions 338 between them, can also take place in trans.

339 In conclusion, the results of the present study illustrate the role of HLA alleles both separately and in combination in immune-mediated diseases, revealing 340 341 potentially new HLA-linked disease phenotypes and providing a data resource for 342 future HLA analyses in independent populations. The results expand the view of 343 the complex genetic structure of HLA, motivating the consideration of allele and 344 gene interactions in risk calculations. These results can serve as starting points 345 for functional studies focusing on mechanistic molecular underpinnings of the discovered associations. 346

# 347 Materials and Methods

# 348 Subjects and clinical endpoints

- 349 The discovery cohort of the study included all biobank participants in the
- 350 FinnGen (<u>www.finngen.fi</u>) data release R3 ( $n_{total} = 146,630$ ) while the independent
- replication cohort comprised the data release R5 (without R3;  $n_{total} = 89,340$ ).
- 352 Numbers of cases and controls for each phenotype are given in the
- 353 Supplementary Table 1. Endpoints with at least 5 cases carrying a given allele in
- both discovery and replication cohorts were included in the analysis. The clinical
- disease endpoint definitions were curated from ICD 9-10, ICD-O-3, the Social
- 356 Insurance Institute (KELA) drug reimbursement codes and ATC-codes as a part of

357 the FinnGen project (finngen.gitbook.io/documentation/methods/endpoints). For

- 358 clarity, the FinnGen phenotypes include many partially overlapping diseases or
- 359 traits, particularly in diabetes and its comorbidities. Thus, the included
- 360 phenotypes are not necessarily independent. All patients and control subjects
- 361 provided an informed consent for biobank research in accordance with the
- 362 Finnish Biobank Act, with the exception of FinnGen legacy samples which were
- approved by the National Supervisory Authority for Welfare and Health (Valvira).
- The FinnGen study protocol was approved by the Ethical Review Board of the
- 365 Hospital District of Helsinki and Uusimaa (Nr HUS/990/2017). All samples and
- 366 individual-level data were pseudonymized and processed in accordance with the
- 367 EU GDPR law.

# 368 Genotyping

- 369 Genotyping of FinnGen samples was performed on a customized ThermoFisher
- 370 Axiom array at the Thermo Fisher genotyping service facility (San Diego, USA).
- 371 Genotype calling and quality control steps are described in
- 372 <u>finngen.gitbook.io/documentation/methods/genotype-imputation</u>. The array
- 373 markes files can be downloaded from <u>www.finngen.fi/en/researchers/genotyping</u>.
- The protocol for genotype liftover to hg38/GRCh38 is described in detail in
- 375 <u>www.protocols.io/view/genotyping-chip-data-lift-over-to-reference-genome-</u>
- 376 <u>xbhfij6?version\_warning=no</u>, and genotype imputation protocol is described in
- 377 <u>www.protocols.io/view/genotype-imputation-workflow-v3-0-xbgfijw</u>.

# 378 HLA allele analysis

- 379 We implemented the PheWAS approach (Denny et al., 2013) for imputed alleles
- of HLA-A, -B, -C, -DRB1, -DQA1, -DQB1 and -DPB1 genes to analyze their
- 381 correlation with 3,355 clinical case-control endpoints in 37 broad disease
- 382 categories. Each analysed phenotype included at least five cases in both
- 383 discovery and replication sets. HLA imputation at four-digit resolution (i.e.
- 384 protein-level) was conducted as described previously (Ritari et al., 2020). Briefly,
- we used HIBAG v1.18.1 (Zheng et al., 2014) R library with a Finnish population-
- 386 specific HLA reference panel (n = 1,150) based on  $\sim$ 4,500 SNPs within the MHC
- region (chr6:28.51-33.48 Mb; hg38/GRCh38), and considered imputation
- 388 posterior probabilities > 0.5 as acceptable. For association analyses, we defined
- 389 the imputed HLA alleles as bi-allelic SNPs and assumed additive effects of allele

388 dosages on the binary phenotype. Logistic regression models were run using 389 SPAtest v3.0.2 (Dey et al., 2017) in R v3.6.3 (R Core Team, 2020) with top 10 390 genetic principal components (PCs), age and sex as covariates. To correct for 391 multiple testing under dependency and to identify associations for validation in 392 the replication cohort, we applied adaptive Benjamini-Hochberg (Benjamini and 393 Hochberg, 2000; Kim and van de Wiel, 2008) procedure to the discovery cohort 394 SPAtest saddlepoint approximated p-values using the R library mutoss v0.1-12 395 (MuToss Coding Team et al., 2017) at FDR < 0.01 threshold. We considered an 396 association valid if the replication p-value was < 0.01 and the effect direction 397 was consistent with the discovery cohort.

398 To evaluate independent contributions of HLA alleles significantly associated with 399 multiple disease categories, we performed conditional analyses that 400 systematically included a phenotype from a different disease category as an 401 additional covariate. In this analysis we used the whole dataset (data release R5) 402 and genome-wide p-value threshold of  $5 \times 10^{-8}$ . To exclude phenotypes in strong 403 correlation with each other from the analysis, we first computed an all-vs-all 404 Pearson's correlation matrix between the phenotypes and removed those having 405 a correlation >0.8 with another phenotype. Association for each HLA allele with a 406 given phenotype was performed by including a different, non-correlating 407 phenotype as a covariate along with age, sex and 10 genetic PCs using SPAtest 408 as described above.

#### 409 HLA diplotype analysis

410 To systematically study how the association effect of the primary risk allele was 411 impacted by other alleles of the same HLA gene, we performed association 412 analyses for HLA allele combinations (termed here as diplotypes). The top risk 413 alleles were identified based on the lowest significant single-allele p-value for 414 each phenotype in the discovery cohort. We performed conditional regression 415 analyses by including all the diplotypes in the same model for a given 416 phenotype. With this approach our aim was to quantify actual allelic effects as 417 distinguished from nonpredisposition to the risk allele. As described above, the 418 top 10 genetic PCs, age and sex were included as other covariates. To identify 419 significant effects relative to the top risk genotype for a given phenotype, we 420 performed a two-tailed Z-test on the obtained conditional logistic regression 421 coefficients (betas) and their standard errors.

# 422 HLA haplotype analysis

- 423 The haplotype analysis was based on the observation that in some phenotypes a 424 significant association was found both in HLA class I and class II genes. To 425 evaluate whether alleles in a class I gene affected the risk of an allele in a class II 426 gene, or vice versa, we considered combinations of alleles from both class I and 427 II. The top risk allele for each phenotype was first identified based on the lowest 428 significant single-allele p-value in the discovery cohort, and then combined with 429 alleles of a HLA gene of a different class (termed here as haplotypes). Thus, the 430 primary risk allele was studied in all available allele combinations of the 431 secondary gene. HLAs were imputed on phased genotype data obtained from 432 genotype imputation, and the combined loci under analysis were selected from 433 the same phase. All haplotypes were included in the same regression model for a 434 given phenotype. Two-tailed Z-test was used to evaluate the significance of the
- 435 haplotoypic effects.

# 436 Data availability

- 437 The FinnGen summary statistics data can be accessed through the Finnish
- 438 Biobanks' FinnBB portal and the FinnGen website
- 439 (<u>https://www.finngen.fi/en/access\_results</u>).

# 440 Code availability

- 441 The analysis code is available at <u>https://github.com/FRCBS/HLA\_PheWAS</u>. The
- 442 FinnGen genotyping and imputation protocol is described at <u>https://doi-</u>
- 443 <u>org.libproxy.helsinki.fi/10.17504/protocols.io.nmndc5e</u>.

# 444 Acknowledgements

- The study was supported by the Academy of Finland, the Finnish Cancer
- 446 Association, VTR funding from the Finnish Government, and Business Finland.
- 447 FinnGen funding statement is available as supplementary information. We are
- 448 grateful to all FinnGen participants for their generous contribution to the project.

- 449 The funders and biobanks had no role in study design, data collection and
- 450 analysis, decision to publish, or preparation of the manuscript.

#### 451 Competing interests

452 The authors declare no competing interests.

#### 453 References

- A. Barr T, Gray M, Gray D. 2012. B Cells: Programmers of CD4 T Cell Responses. IDDT **12**:222–231. doi:10.2174/187152612800564446
- Bach J-F. 2018. The hygiene hypothesis in autoimmunity: the role of pathogens and commensals. *Nat Rev Immunol* **18**:105–120. doi:10.1038/nri.2017.111
- Benjamini Y, Hochberg Y. 2000. On the Adaptive Control of the False Discovery Rate in Multiple Testing With Independent Statistics. *Journal of Educational and Behavioral Statistics* **25**:60–83. doi:10.3102/10769986025001060
- Bettencourt A, Carvalho C, Leal B, Brás S, Lopes D, Martins da Silva A, Santos E, Torres T, Almeida I, Farinha F, Barbosa P, Marinho A, Selores M, Correia J, Vasconcelos C, Costa PP, da Silva BM. 2015. The Protective Role of HLA-DRB1 13 in Autoimmune Diseases. *Journal of Immunology Research* 2015:1–6. doi:10.1155/2015/948723
- Chheda H, Palta P, Pirinen M, McCarthy S, Walter K, Koskinen S, Salomaa V, Daly M, Durbin R, Palotie A, Aittokallio T, Ripatti S. 2017. Whole-genome view of the consequences of a population bottleneck using 2926 genome sequences from Finland and United Kingdom. *Eur J Hum Genet* 25:477– 484. doi:10.1038/ejhg.2016.205
- Creary LE, Gangavarapu S, Mallempati KC, Montero-Martín G, Caillier SJ, Santaniello A, Hollenbach JA, Oksenberg JR, Fernández-Viña MA. 2019. Next-generation sequencing reveals new information about HLA allele and haplotype diversity in a large European American population. *Human Immunology* **80**:807–822. doi:10.1016/j.humimm.2019.07.275
- D'Antonio M, Reyna J, Jakubosky D, Donovan MK, Bonder M-J, Matsui H, Stegle O, Nariai N, D'Antonio-Chronowska A, Frazer KA. 2019. Systematic genetic analysis of the MHC region reveals mechanistic underpinnings of HLA type associations with disease. *eLife* **8**:e48476. doi:10.7554/eLife.48476
- Dendrou CA, Petersen J, Rossjohn J, Fugger L. 2018. HLA variation and disease. Nat Rev Immunol **18**:325–339. doi:10.1038/nri.2017.143
- Denny JC, Bastarache L, Ritchie MD, Carroll RJ, Zink R, Mosley JD, Field JR, Pulley JM, Ramirez AH, Bowton E, Basford MA, Carrell DS, Peissig PL, Kho AN, Pacheco JA, Rasmussen LV, Crosslin DR, Crane PK, Pathak J, Bielinski SJ, Pendergrass SA, Xu H, Hindorff LA, Li R, Manolio TA, Chute CG, Chisholm RL, Larson EB, Jarvik GP, Brilliant MH, McCarty CA, Kullo IJ, Haines JL, Crawford DC, Masys DR, Roden DM. 2013. Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol **31**:1102–1111. doi:10.1038/nbt.2749
- Dey R, Schmidt EM, Abecasis GR, Lee S. 2017. A Fast and Accurate Algorithm to Test for Binary Phenotypes and Its Application to PheWAS. *The American Journal of Human Genetics* **101**:37–49. doi:10.1016/j.ajhg.2017.05.014

- Diogo D, Tian C, Franklin CS, Alanne-Kinnunen M, March M, Spencer CCA, Vangjeli C, Weale ME, Mattsson H, Kilpeläinen E, Sleiman PMA, Reilly DF, McElwee J, Maranville JC, Chatteriee AK, Bhandari A, Nguven K-DH. Estrada K, Reeve M-P, Hutz J, Bing N, John S, MacArthur DG, Salomaa V, Ripatti S, Hakonarson H, Daly MJ, Palotie A, Hinds DA, Donnelly P, Fox CS, Day-Williams AG, Plenge RM, Runz H. 2018. Phenome-wide association studies across large population cohorts support drug target validation. Nat Commun 9:4285. doi:10.1038/s41467-018-06540-3
- Eike MC, Becker T, Humphreys K, Olsson M, Lie BA. 2009. Conditional analyses on the T1DGC MHC dataset: novel associations with type 1 diabetes around HLA-G and confirmation of HLA-B. Genes Immun 10:56-67. doi:10.1038/gene.2008.74
- Ercolini AM, Miller SD. 2009. The role of infections in autoimmune disease. Clinical & Experimental Immunology 155:1-15. doi:10.1111/j.1365-2249.2008.03834.x
- Furukawa H, Oka S, Tsuchiya N, Shimada K, Hashimoto A, Tohma S, Kawasaki A. 2017. The role of common protective alleles HLA-DRB1\*13 among systemic autoimmune diseases. Genes Immun 18:1-7. doi:10.1038/gene.2016.40
- Gregersen PK, Silver J, Winchester RJ. 1987. The shared epitope hypothesis. an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis & Rheumatism 30:1205-1213. doi:10.1002/art.1780301102
- Hirata J, Hosomichi K, Sakaue S, Kanai M, Nakaoka H, Ishigaki K, Suzuki K, Akiyama M, Kishikawa T, Ogawa K, Masuda T, Yamamoto K, Hirata M, Matsuda K. Momozawa Y. Inoue I. Kubo M. Kamatani Y. Okada Y. 2019. Genetic and phenotypic landscape of the major histocompatibility complex region in the Japanese population. Nat Genet 51:470-480. doi:10.1038/s41588-018-0336-0
- Hu X, Deutsch AJ, Lenz TL, Onengut-Gumuscu S, Han B, Chen W-M, Howson IMM, Todd JA, de Bakker PIW, Rich SS, Raychaudhuri S. 2015. Additive and interaction effects at three amino acid positions in HLA-DQ and HLA-DR molecules drive type 1 diabetes risk. Nat Genet 47:898-905. doi:10.1038/ ng.3353
- Hurley CK, Kempenich J, Wadsworth K, Sauter J, Hofmann JA, Schefzyk D, Schmidt AH, Galarza P, Cardozo MBR, Dudkiewicz M, Houdova L, Jindra P, Sorensen BS, Jagannathan L, Mathur A, Linjama T, Torosian T, Freudenberger R, Manolis A, Mavrommatis J, Cereb N, Manor S, Shriki N, Sacchi N, Ameen R, Fisher R, Dunckley H, Andersen I, Alaskar A, Alzahrani M, Hajeer A, Jawdat D, Nicoloso G, Kupatawintu P, Cho L, Kaur A, Bengtsson M, Dehn J. 2020. Common, intermediate and well-documented HLA alleles in world populations: CIWD version 3.0.0. HLA 95:516-531. doi:10.1111/tan.13811
- Karnes JH, Bastarache L, Shaffer CM, Gaudieri S, Xu Y, Glazer AM, Mosley JD, Zhao S, Ravchaudhuri S, Mallal S, Ye Z, Mayer IG, Brilliant MH, Hebbring SI, Roden DM, Phillips EJ, Denny JC. 2017. Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants. Sci Transl Med 9:eaai8708. doi:10.1126/scitranslmed.aai8708
- Kim KI, van de Wiel MA. 2008. Effects of dependence in high-dimensional multiple testing problems. BMC Bioinformatics 9:114. doi:10.1186/1471-2105-9-114
- Lenz TL, Deutsch AJ, Han B, Hu X, Okada Y, Eyre S, Knapp M, Zhernakova A, Huizinga TWJ, Abecasis G, Becker J, Boeckxstaens GE, Chen W-M, Franke A, Gladman DD, Gockel I, Gutierrez-Achury J, Martin J, Nair RP, Nöthen MM, Onengut-Gumuscu S, Rahman P, Rantapää-Dahlqvist S, Stuart PE, Tsoi LC, van Heel DA, Worthington J, Wouters MM, Klareskog L, Elder JT, Gregersen

PK, Schumacher J, Rich SS, Wijmenga C, Sunyaev SR, de Bakker PIW, Raychaudhuri S. 2015. Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases. Nat Genet 47:1085-1090. doi:10.1038/ng.3379

- Linjama T, Eberhard H-P, Peräsaari J, Müller C, Korhonen M. 2018. A European HLA Isolate and Its Implications for Hematopoietic Stem Cell Transplant Donor Procurement. Biology of Blood and Marrow Transplantation 24:587-593. doi:10.1016/j.bbmt.2017.10.010
- Liu J, Ye Z, Mayer JG, Hoch BA, Green C, Rolak L, Cold C, Khor S-S, Zheng X, Miyagawa T, Tokunaga K, Brilliant MH, Hebbring SI, 2016, Phenome-wide association study maps new diseases to the human major histocompatibility complex region. / Med Genet 53:681-689. doi:10.1136/jmedgenet-2016-103867
- Matzaraki V, Kumar V, Wijmenga C, Zhernakova A. 2017. The MHC locus and genetic susceptibility to autoimmune and infectious diseases. Genome Biol 18:76. doi:10.1186/s13059-017-1207-1
- Mikk M-L, Heikkinen T, El-Amir MI, Kiviniemi M, Laine A-P, Härkönen T, Veijola R, Toppari J, Knip M, Ilonen J, the Finnish Paediatric Diabetes Register. 2017. The association of the HLA-A\*24:02, B\*39:01 and B\*39:06 alleles with type 1 diabetes is restricted to specific HLA-DR/DQ haplotypes in Finns. HLA 89:215-224. doi:10.1111/tan.12967
- MuToss Coding Team, Blanchard G, Dickhaus T, Hack N, Konietschke F, Rohmeyer K, Rosenblatt J, Scheer M, Werft W. 2017. mutoss: Unified Multiple Testing Procedures.
- Nasa GL, Cottoni F, Mulargia M, Carcassi C, Vacca A, Pizzati A, Ledda A, Montesu MA, Cerimele D, Contu L, 1995, HLA antigen distribution in different clinical subgroups demonstrates genetic heterogeneity in lichen planus. British Journal of Dermatology 132:897-900. doi:10.1111/j.1365-2133.1995.tb16945.x
- Noble JA, Valdes AM. 2011. Genetics of the HLA Region in the Prediction of Type 1 Diabetes. Curr Diab Rep 11:533-542. doi:10.1007/s11892-011-0223-x
- Okada Y, Suzuki A, Ikari K, Terao C, Kochi Y, Ohmura K, Higasa K, Akiyama M, Ashikawa K, Kanai M, Hirata J, Suita N, Teo Y-Y, Xu H, Bae S-C, Takahashi A, Momozawa Y, Matsuda K, Momohara S, Taniguchi A, Yamada R, Mimori T, Kubo M, Brown MA, Raychaudhuri S, Matsuda F, Yamanaka H, Kamatani Y, Yamamoto K. 2016. Contribution of a Non-classical HLA Gene, HLA-DOA, to the Risk of Rheumatoid Arthritis. The American Journal of Human Genetics 99:366-374. doi:10.1016/j.ajhg.2016.06.019
- Oldstone MBA. 1998. Molecular mimicry and immune-mediated diseases. FASEB j 12:1255-1265. doi:10.1096/fasebj.12.13.1255
- Porter K, Klouda P, Scully C, Bidwell J, Porter S. 1993. Class I and II HLA antigens in British patients with oral lichen planus. Oral Surgery, Oral Medicine, Oral Pathology 75:176-180. doi:10.1016/0030-4220(93)90090-Q
- Pugliese A, Gianani R, Moromisato R, Awdeh ZL, Alper CA, Erlich HA, Jackson RA, Eisenbarth GS. 1995. HLA-DQB1\*0602 Is Associated With Dominant Protection From Diabetes Even Among Islet Cell Antibody-Positive First-Degree Relatives of Patients with IDDM. Diabetes 44:608-613. doi:10.2337/diab.44.6.608
- Queiro R, Gonzalez S, López-Larrea C, Alperi M, Sarasgueta C, Riestra J, Ballina J. 2006. HLA-C locus alleles may modulate the clinical expression of psoriatic arthritis. Arthritis Res Ther 8:R185. doi:10.1186/ar2097
- R Core Team. 2020. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.
- Raychaudhuri S, Sandor C, Stahl EA, Freudenberg J, Lee H-S, Jia X, Alfredsson L, Padyukov L, Klareskog L, Worthington J, Siminovitch KA, Bae S-C, Plenge

RM, Gregersen PK, de Bakker PIW. 2012. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 44:291-296. doi:10.1038/ng.1076

- Ritari J, Hyvärinen K, Clancy J, FinnGen, Partanen J, Koskela S. 2020. Increasing accuracy of HLA imputation by a population-specific reference panel in a FinnGen biobank cohort. NAR Genomics and Bioinformatics 2:Igaa030. doi:10.1093/nargab/lgaa030
- Sfriso P, Ghirardello A, Botsios C, Tonon M, Zen M, Bassi N, Bassetto F, Doria A. 2010. Infections and autoimmunity: the multifaceted relationship. Journal of Leukocyte Biology 87:385-395. doi:10.1189/ilb.0709517
- The International HIV Controllers Study. 2010. The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation. Science 330:1551-1557. doi:10.1126/science.1195271
- The MHC sequencing consortium, 1999, Complete sequence and gene map of a human major histocompatibility complex. Nature 401:921-923. doi:10.1038/44853
- Thorsby E. 2009. A short history of HLA. *Tissue Antigens* **74**:101–116. doi:10.1111/j.1399-0039.2009.01291.x
- Tian C, Hromatka BS, Kiefer AK, Eriksson N, Noble SM, Tung JY, Hinds DA. 2017. Genome-wide association and HLA region fine-mapping studies identify susceptibility loci for multiple common infections. *Nat Commun* **8**:599. doi:10.1038/s41467-017-00257-5
- Trowsdale J, Knight JC. 2013. Major Histocompatibility Complex Genomics and Human Disease. Annu Rev Genom Hum Genet 14:301-323. doi:10.1146/annurev-genom-091212-153455
- Tsai S. Santamaria P. 2013. MHC Class II Polymorphisms, Autoreactive T-Cells. and Autoimmunity. Front Immunol 4. doi:10.3389/fimmu.2013.00321
- Tuokko J, Reijonen H, Ilonen J, Anttila K, Nikkari S, Mottonen T, Yli-Kerttula U, Toivanen A. 1997. Increase of HLA-DRB1\*0408 and -DQB1\*0301 in HLA-B27 positive reactive arthritis. Annals of the Rheumatic Diseases 56:37-40. doi:10.1136/ard.56.1.37
- van der Helm-van Mil AHM, Huizinga TWJ, Schreuder GMTh, Breedveld FC, de Vries RRP, Toes REM. 2005. An independent role of protective HLA class II alleles in rheumatoid arthritis severity and susceptibility. Arthritis Rheum 52:2637-2644. doi:10.1002/art.21272
- van Lummel M, Buis DTP, Ringeling C, de Ru AH, Pool J, Papadopoulos GK, van Veelen PA, Reijonen H, Drijfhout JW, Roep BO. 2019. Epitope Stealing as a Mechanism of Dominant Protection by HLA-DQ6 in Type 1 Diabetes. Diabetes 68:787-795. doi:10.2337/db18-0501
- Verma A, Lucas A, Verma SS, Zhang Y, Josyula N, Khan A, Hartzel DN, Lavage DR, Leader J, Ritchie MD, Pendergrass SA. 2018. PheWAS and Beyond: The Landscape of Associations with Medical Diagnoses and Clinical Measures across 38,662 Individuals from Geisinger. The American Journal of Human Genetics 102:592-608. doi:10.1016/j.ajhg.2018.02.017
- Wu J-S, James J, Wei Qiu, Castley A, Christiansen FT, Carroll WM, Mastaglia FL, Kermode AG. 2010. Influence of HLA-DRB1 allele heterogeneity on disease risk and clinical course in a West Australian MS cohort: a high-resolution genotyping study. *Mult Scler* **16**:526–532. doi:10.1177/1352458510362997
- Wucherpfennig KW, Strominger JL. 1995. Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein. Cell 80:695-705. doi:10.1016/0092-8674(95)90348-8
- Zheng X, Shen J, Cox C, Wakefield JC, Ehm MG, Nelson MR, Weir BS. 2014. HIBAG —HLA genotype imputation with attribute bagging. *Pharmacogenomics J* 14:192-200. doi:10.1038/tpj.2013.18